GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » Revenue per Share

iCo Therapeutics (iCo Therapeutics) Revenue per Share : $0.00 (TTM As of Mar. 2021)


View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics Revenue per Share?

iCo Therapeutics's revenue per share for the three months ended in Mar. 2021 was $0.00. iCo Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Mar. 2021 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for iCo Therapeutics's Revenue per Share or its related term are showing as below:

ICOTF's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.4
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

iCo Therapeutics Revenue per Share Historical Data

The historical data trend for iCo Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics Revenue per Share Chart

iCo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

iCo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of iCo Therapeutics's Revenue per Share

For the Biotechnology subindustry, iCo Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iCo Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's PS Ratio falls into.



iCo Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

iCo Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2020 is calculated as

Revenue Per Share (A: Dec. 2020 )=Revenue (A: Dec. 2020 )/Shares Outstanding (Diluted Average) (A: Dec. 2020 )
=0/7.687
=0.00

iCo Therapeutics's Revenue Per Share for the quarter that ended in Mar. 2021 is calculated as

Revenue Per Share (Q: Mar. 2021 )=Revenue (Q: Mar. 2021 )/Shares Outstanding (Diluted Average) (Q: Mar. 2021 )
=0/8.053
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iCo Therapeutics  (GREY:ICOTF) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


iCo Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


iCo Therapeutics (iCo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines